| Nelonemdaz for Patients With Acute Ischemic Stroke Undergoing Endovascular Reperfusion Therapy: A Randomized Phase II Trial.Stroke | PMID 36065810PMC9586831 | 2022-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Survival with novel hormonal therapies in patients with nonmetastatic castration-resistant prostate cancer: indirect comparison of three randomized phase-III trials.World J Urol | PMID 36083316无 PMCID | 2022-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Nab-Paclitaxel for Previously Treated Advanced Non-Small Cell Lung Cancer: Analysis of Safety and Efficacy for Patients With Renal Impairment.Clin Lung Cancer | PMID 36114096无 PMCID | 2022-Nov | 0.70 | While the study meets criteria for oncology, human, randomized, Phase 3, drug intervention, and original result, the abstract does not explicitly present a primary time-to-event efficacy endpoint (like OS or PFS with KM or HR) for the main trial population. The reported efficacy comparison is described generally ('difference in treatment efficacy... was similar to that among the overall study population'), but the specific endpoint and its time-to-event nature are not confirmed. Therefore, eligibility cannot be fully established. | 待处理 |
| Safety Findings in Lasmiditan as a Novel Acute Treatment of Migraine in Chinese Patients: A Post Hoc Analysis of the Randomized Controlled Phase 3 CENTURION Trial.Adv Ther | PMID 36114949无 PMCID | 2022-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study.BioDrugs | PMID 36114990PMC9649481 | 2022-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasis.Int Immunopharmacol | PMID 36126411无 PMCID | 2022-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer.Oral Oncol | PMID 36126605无 PMCID | 2022-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| The obesity paradox: Retinopathy, obesity, and circulating risk markers in youth with type 2 diabetes in the TODAY Study.J Diabetes Complications | PMID 36150365PMC12396272 | 2022-Nov | 0.90 | The record describes a non-oncology clinical trial (TODAY Study) focused on type 2 diabetes and diabetic retinopathy in adolescents. Although it is a randomized, Phase III study in humans, the subject matter and outcomes are not relevant to oncology Kaplan-Meier digitization. | 待处理 |
| Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.Lancet Diabetes Endocrinol | PMID 36152639无 PMCID | 2022-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The efficacy and safety of DW1601 in patients with acute bronchitis: a multi-center, randomized, double-blind, phase III clinical trial.Korean J Intern Med | PMID 36153858PMC9666245 | 2022-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial.BioDrugs | PMID 36169807PMC9649513 | 2022-Nov | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| A cross-sectional study of participant recruitment rates in published phase III influenza therapeutic randomized controlled trials conducted in the clinical setting.Am J Emerg Med | PMID 36174486无 PMCID | 2022-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.Lancet Oncol | PMID 36183733无 PMCID | 2022-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.Eur J Cancer | PMID 36202690无 PMCID | 2022-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.Lancet Oncol | PMID 36265502无 PMCID | 2022-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.Lancet Oncol | PMID 36265504无 PMCID | 2022-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.Lancet Haematol | PMID 36328040无 PMCID | 2022-Nov | 0.85 | The trial is a phase 3 RCT with drug intervention, but the primary efficacy endpoint (MRD negativity) is not a time-to-event endpoint, and no time-to-event primary/key secondary endpoint is reported in the provided abstract. | 待处理 |
| The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.CNS Drugs | PMID 36346534PMC9641300 | 2022-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of Tregopil, a novel, ultra-rapid acting oral prandial insulin analog, as part of a basal-bolus regimen in type 2 diabetes: a randomized, active-controlled phase 2/3 study.Expert Opin Pharmacother | PMID 36352762无 PMCID | 2022-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bilateral Effect of OC-01 (Varenicline Solution) Nasal Spray for Treatment of Signs and Symptoms in Individuals with Mild, Moderate, and Severe Dry Eye Disease.Clin Ther | PMID 36763994无 PMCID | 2022-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Preliminary Analysis on the Feasibility and Short-Term Efficacy of a Phase-III RCT on Mindfulness Added to Treatment as Usual for Patients with Chronic Migraine and Medication Overuse Headache.Int J Environ Res Public Health | PMID 36360996PMC9653620 | 2022-Oct-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.Lancet | PMID 36522207无 PMCID | 2022-Oct-29 | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea.Lancet | PMID 36522208无 PMCID | 2022-Oct-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Mortality after multivessel revascularisation involving the proximal left anterior descending artery.Heart | PMID 35732441PMC9626917 | 2022-Oct-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.Blood | PMID 35917453PMC10653009 | 2022-Oct-27 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| VoiceS: voice quality after transoral CO2 laser surgery versus single vocal cord irradiation for unilateral stage 0 and I glottic larynx cancer-a randomized phase III trial.Trials | PMID 36303192PMC9615245 | 2022-Oct-27 | 0.95 | The study is a randomized phase III trial in human laryngeal cancer, but it lacks a drug-containing intervention (comparing radiotherapy vs. surgery) and its primary endpoint is a patient-reported voice quality outcome, not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The abstract describes the study protocol, not final results. | 待处理 |
| Immunogenicity and safety of high-dose quadrivalent influenza vaccine in older adults in Taiwan: A phase III, randomized, multi-center study.Vaccine | PMID 36216650无 PMCID | 2022-Oct-26 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial.J Hematol Oncol | PMID 36289532PMC9598030 | 2022-Oct-26 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Monofilament suture versus braided suture thread to improve pregnancy outcomes after vaginal cervical cerclage (C-STICH): a pragmatic randomised, controlled, phase 3, superiority trial.Lancet | PMID 36273481无 PMCID | 2022-Oct-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.N Engl J Med | PMID 36260792无 PMCID | 2022-Oct-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN).Vaccine | PMID 36150974无 PMCID | 2022-Oct-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial.Int J Cancer | PMID 35583992无 PMCID | 2022-Oct-15 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Use of mobile data collection systems within large-scale epidemiological field trials: findings and lessons-learned from a vector control trial in Iquitos, Peru.BMC Public Health | PMID 36243698PMC9571464 | 2022-Oct-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630.Clin Cancer Res | PMID 35980349PMC9561604 | 2022-Oct-14 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial.Elife | PMID 36226829PMC9596164 | 2022-Oct-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| AmBisome Monotherapy and Combination AmBisome-Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial.Clin Infect Dis | PMID 35147680PMC9555838 | 2022-Oct-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.J Clin Oncol | PMID 35452273无 PMCID | 2022-Oct-10 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial.J Clin Oncol | PMID 35512259无 PMCID | 2022-Oct-10 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.J Clin Oncol | PMID 36027558无 PMCID | 2022-Oct-10 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031).Jpn J Clin Oncol | PMID 35750038PMC9538755 | 2022-Oct-06 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| A phase III clinical trial evaluating efficacy and safety of minimal residual disease-based risk stratification for children with acute myeloid leukemia, incorporating a randomized study of gemtuzumab ozogamicin in combination with post-induction chemotherapy for non-low-risk patients (JPLSG-AML-20).Jpn J Clin Oncol | PMID 35809896无 PMCID | 2022-Oct-06 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C.World J Clin Cases | PMID 36246814PMC9561570 | 2022-Oct-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Five-year results of Amaze: a randomized controlled trial of adjunct surgery for atrial fibrillation.Eur J Cardiothorac Surg | PMID 35348642PMC9615434 | 2022-Oct-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Custodiol-N versus Custodiol: a prospective randomized double-blind multicentre phase III trial in patients undergoing elective coronary bypass surgery.Eur J Cardiothorac Surg | PMID 35579350无 PMCID | 2022-Oct-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial.JAMA | PMID 36194218PMC9533186 | 2022-Oct-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study).Clin Cancer Res | PMID 35929990PMC9527503 | 2022-Oct-03 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial.J Clin Psychiatry | PMID 36198061无 PMCID | 2022-Oct-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.JAMA Netw Open | PMID 36287567PMC9606845 | 2022-Oct-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Weight-Based Compared With Fixed-Dose Enoxaparin Prophylaxis After Cesarean Delivery: A Randomized Controlled Trial.Obstet Gynecol | PMID 36075079PMC10473241 | 2022-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.Haematologica | PMID 35354247PMC9521240 | 2022-Oct-01 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |